

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A crystal comprising a purified polypeptide of SEQ ID NO: 1 co-crystalized with the FGF-1 of SEQ ID NO: 17 having tetragonal space group symmetry P1 and the unit cell dimensions of $a=62.55\text{\AA}$, $b=64.14$, $\alpha=93.40^\circ$, $\beta=111.17^\circ$, and $\gamma=97.18^\circ$ ~~which includes an extracellular domain of a receptor protein tyrosine kinase.~~

2. (Currently Amended) A crystal of FGFR1 D2-D3 complexed with FGF2, wherein said crystal is characterized by the atomic structure coordinates of Table 1. ~~The crystal of claim 1 wherein the extracellular domain comprises one or more Ig-like domains.~~

3. (Currently Amended) A crystal of FGFR1 D2-D3 complexed with FGF1, wherein said crystal is characterized by the atomic structure coordinates of Table 2. ~~The crystal of claim 2, wherein the receptor protein tyrosine kinase is a fibroblast growth factor receptor.~~

4 – 89. (Canceled)